Myxoid liposarcomas: systemic treatment options
EF Nassif, EZ Keung, P Thirasastr… - Current treatment options …, 2023 - Springer
Opinion Statement Myxoid/round-cell liposarcoma (MRCL) account for 30% of liposarcomas
and are the most chemo-sensitive subtype of liposarcoma. The 5-year local relapse and …
and are the most chemo-sensitive subtype of liposarcoma. The 5-year local relapse and …
Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review
T Assi, C Ngo, M Faron, B Verret, A Lévy… - … Treatment Options in …, 2023 - Springer
Opinion statement The therapeutic approach of pleomorphic liposarcoma (PLPS), a rare
high-grade subgroup of soft tissue sarcoma, is commonly extrapolated from the …
high-grade subgroup of soft tissue sarcoma, is commonly extrapolated from the …
Efficacy of eribulin plus gemcitabine combination in L-sarcomas
M López-Álvarez, C González-Aguilera… - International journal of …, 2022 - mdpi.com
Although the overall survival of advanced soft-tissue sarcoma (STS) patients has increased
in recent years, the median progression-free survival is lower than 5 months, meaning that …
in recent years, the median progression-free survival is lower than 5 months, meaning that …
[PDF][PDF] Prognostic factors and nomogram construction for primary retroperitoneal myxoid/round cell liposarcoma: an analysis of population-based data
A Zhuang, Y Cheng, Z Xi, G Yan, Y Wang… - Journal of Clinical and …, 2024 - jctres.com
Background: It has been reported that the prognosis for myxoid/round cell liposarcoma
(MLPS/RCLPS) is inconsistent across different sites. However, there are neither prognostic …
(MLPS/RCLPS) is inconsistent across different sites. However, there are neither prognostic …
On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the …
Background Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have been established as
a standard treatment for hormone receptor (HR)-positive, human epidermal growth factor …
a standard treatment for hormone receptor (HR)-positive, human epidermal growth factor …
Not All Leiomyosarcomas Are the Same: How to Best Classify LMS
A Hickman, BL Siontis - Current Treatment Options in Oncology, 2023 - Springer
Opinion statement Leiomyosarcoma arises from smooth muscle and represents one of the
most common soft tissue sarcomas. Despite aggressive multimodality care, over half of the …
most common soft tissue sarcomas. Despite aggressive multimodality care, over half of the …
[PDF][PDF] Papel del Tratamiento con Gemcitabina y Dacarbazina en Sarcomas: Factores Pronósticos y Predictivos de Respuesta
J Martínez Trufero - zaguan.unizar.es
El desarrollo de este proyecto de investigación del doctorando Ibón Gurruchaga Sotés se
ha desarrollado entre los años 2019 a 2024 ajustándose a los requisitos exigidos por la …
ha desarrollado entre los años 2019 a 2024 ajustándose a los requisitos exigidos por la …
Papel del Tratamiento con Gemcitabina y Dacarbazina en Sarcomas: Factores Pronósticos y Predictivos de Respuesta
I Gurruchaga Sotés, J Martínez Trufero - zaguan.unizar.es
Antecedentes: La combinación de gemcitabina y dacarbazina ha mostrado eficacia en
términos de supervivencia libre de progresión (SLP) y supervivencia global (SG) para los …
términos de supervivencia libre de progresión (SLP) y supervivencia global (SG) para los …
[PDF][PDF] Chang Gon Kim1, Min Hwan Kim1, Jee Hung Kim2, 3, Seul‑Gi Kim1, Gun Min Kim1, Tae Yeong Kim4, Won‑Ji Ryu4, Jee Ye Kim5, Hyung Seok Park5, Seho …
J Jeong, J Sohn - 2023 - breast-cancer-research …
Background Cyclin‑dependent kinase 4 and 6 (CDK4/6) inhibitors have been established as
a standard treatment for hormone receptor (HR)‑positive, human epidermal growth factor …
a standard treatment for hormone receptor (HR)‑positive, human epidermal growth factor …